Delving into the Latest Updates on Waterstone Pharmaceuticals (Wuhan) Co., Ltd. with Synapse

Overview

Basic Info

Introduction

Waterstone Pharmaceuticals is an American company that operates out of Wuhan, China. The company specializes in research, development, and manufacturing of pharmaceutical products. Its activities include drug discovery of new chemical entities, custom development and manufacturing services, and the production of generic drugs.

Tags

Endocrinology and Metabolic Disease

Other Diseases

Immune System Diseases

Small molecule drug

Synthetic peptide

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Endocrinology and Metabolic Disease	5
Immune System Diseases	2
Nervous System Diseases	1
Hemic and Lymphatic Diseases	1
Infectious Diseases	1

Top 5 Drug Type	Count

Small molecule drug	6
Synthetic peptide	1

Top 5 Target	Count

Potassium channel	1
CYPA(Cyclophilin A)	1

主要目的：在中国健康参与者空腹状态下评价WS016干混悬剂对非奈利酮片、非布司他片、沙库巴曲缬沙坦钠片、左甲状腺素钠片、华法林钠片、苯磺酸氨氯地平片、达比加群酯胶囊、他克莫司胶囊、炔雌醇片、吲达帕胺片、盐酸环丙沙星片、阿哌沙班片、甲氧苄啶片药代动力学的影响；餐后状态下评价WS016干混悬剂对盐酸西那卡塞片、盐酸二甲双胍片、盐酸伊伐布雷定片、盐酸维拉帕米片药代动力学的影响。次要研究目的：评价在中国健康参与者空腹状态下服用非奈利酮片、非布司他片、沙库巴曲缬沙坦钠片、左甲状腺素钠片、华法林钠片、苯磺酸氨氯地平片、达比加群酯胶囊、他克莫司胶囊、炔雌醇片、吲达帕胺片、盐酸环丙沙星片、阿哌沙班片、甲氧苄啶片及WS016干混悬剂，餐后状态下服用盐酸西那卡塞片、盐酸二甲双胍片、盐酸伊伐布雷定片、盐酸维拉帕米片及WS016干混悬剂联合用药或合并用药后的安全性。

[Translation]

Primary Objective: To evaluate the effects of WS016 dry suspension on the pharmacokinetics of phenelzine tablets, febuxostat tablets, sacubitril/valsartan sodium tablets, levothyroxine sodium tablets, warfarin sodium tablets, amlodipine besylate tablets, dabigatran etexilate capsules, tacrolimus capsules, ethinylestradiol tablets, indapamide tablets, ciprofloxacin hydrochloride tablets, apixaban tablets, and trimethoprim tablets in healthy Chinese participants under fasting conditions; and to evaluate the effects of WS016 dry suspension on the pharmacokinetics of cinacalcet hydrochloride tablets, metformin hydrochloride tablets, ivabradine hydrochloride tablets, and verapamil hydrochloride tablets under postprandial conditions. Secondary study objective: To evaluate the safety of fenelazolone tablets, febuxostat tablets, sacubitril/valsartan sodium tablets, levothyroxine sodium tablets, warfarin sodium tablets, amlodipine besylate tablets, dabigatran etexilate capsules, tacrolimus capsules, ethinylestradiol tablets, indapamide tablets, ciprofloxacin hydrochloride tablets, apixaban tablets, trimethoprim tablets, and WS016 dry suspension in healthy Chinese participants under fasting conditions, and in combination or combined administration of cinacalcet hydrochloride tablets, metformin hydrochloride tablets, ivabradine hydrochloride tablets, verapamil hydrochloride tablets, and WS016 dry suspension under postprandial conditions.

Start Date16 Nov 2025

Sponsor / Collaborator

Waterstone Pharmaceuticals (HuBei) Co., Ltd.

[+1]

CTR20243892

/ CompletedPhase 1

一项在健康青年及老年受试者中评价WS635单次口服给药的药代动力学特征和安全性的I期、单中心、单臂、开放研究

[Translation] A Phase I, single-center, single-arm, open-label study to evaluate the pharmacokinetic characteristics and safety of a single oral dose of WS635 in healthy young and elderly subjects

主要目的：评价WS635在中国健康青年受试者中的PK特征；比较WS635在青年及老年健康受试者中的PK特征。次要目的：评价WS635在青年及老年健康受试者中的安全性

[Translation]

Primary objective: To evaluate the PK characteristics of WS635 in healthy young Chinese subjects; to compare the PK characteristics of WS635 in young and elderly healthy subjects. Secondary objective: To evaluate the safety of WS635 in young and elderly healthy subjects

Start Date25 Dec 2024

Sponsor / Collaborator

Waterstone Pharmaceuticals (Wuhan) Co., Ltd.

NCT07251309

/ RecruitingPhase 3

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Clinical Study to Evaluate the Efficacy and Safety of WS016 in Patients With Hyperkalemia

This clinical trial consists of 2 parts, Part A and Part B. Part A consists of a 2-day randomized, double-blind, placebo-controlled corrective phase (CP) and a 28-day randomized, double-blind, placebo-controlled maintenance phase (MP). Part B (open-label extension, OLE) is an open-label, 11-month extension study carried out in participants who come from Part A and meet certain inclusion criteria.

Start Date23 Dec 2024

Sponsor / Collaborator

Waterstone Pharmaceuticals (HuBei) Co., Ltd.

100 Clinical Results associated with Waterstone Pharmaceuticals (Wuhan) Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Waterstone Pharmaceuticals (Wuhan) Co., Ltd.

Login to view more data

100 Deals associated with Waterstone Pharmaceuticals (Wuhan) Co., Ltd.

Login to view more data

100 Translational Medicine associated with Waterstone Pharmaceuticals (Wuhan) Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 27 Dec 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

3

Phase 1

Phase 3

1

2

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

WS016 ( Potassium channel )	Hyperkalemia More	Phase 3
WS-012	Cholangitis, Sclerosing More	Phase 1
WS-015	Hyperuricemia More	Phase 1
WS-635 ( CYPA )	Emergence Delirium More	Phase 1
WS020	Tumor Lysis Syndrome More	Discovery